RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma

被引：0
|
作者：
Jiajun Wang
Sihong Zhang
Ying Wang
Yanjun Zhu
Xianglai Xu
Jianming Guo
机构：
[1] Fudan University,Department of Urology, Zhongshan Hospital
[2] Fudan University,Department of Critical Care Medicine, Zhongshan Hospital
来源：
BMC Urology | / 24卷
关键词：
Renal cell carcinoma; Runt-related transcription factor 3; Immune checkpoint inhibition plus tyrosine kinase inhibition; Immune evasion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma
    Wang, Jiajun
    Zhang, Sihong
    Wang, Ying
    Zhu, Yanjun
    Xu, Xianglai
    Guo, Jianming
    BMC UROLOGY, 2024, 24 (01)
  • [2] Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
    Yang, Yuanquan
    Psutka, Sarah P.
    Parikh, Anish B.
    Li, Mingjia
    Collier, Katharine
    Miah, Abdul
    Mori, Sherry, V
    Hinkley, Megan
    Tykodi, Scott S.
    Hall, Evan
    Thompson, John A.
    Yin, Ming
    CANCER MEDICINE, 2022, 11 (16): : 3106 - 3114
  • [3] Thymidine kinase 1 indicates resistance to immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma
    Wang, Jiajun
    Xu, Xianglai
    Wang, Ying
    Zhu, Yanjun
    CELLULAR ONCOLOGY, 2025,
  • [4] Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
    Xu, Yunze
    Kong, Wen
    Cao, Ming
    Wang, Jieying
    Wang, Zaoyu
    Zheng, Liang
    Wu, Xiaoyu
    Cheng, Rongrong
    He, Wei
    Yang, Bo
    Dong, Baijun
    Pan, Jiahua
    Chen, Yonghui
    Huang, Jiwei
    Jiang, Chen
    Zhai, Wei
    Li, Fangzhou
    Chen, Ruohua
    Zhou, Xiang
    Wu, Guangyu
    Geng, Xiaochuan
    Chen, Jiasheng
    An, Huimin
    Yuan, Yichu
    Xu, Tianyuan
    Chen, Dongning
    Lin, Dengqiang
    Xu, Lieyu
    Huang, Kangbo
    Peng, Ling
    Yu, Yanfei
    Tai, Shengcheng
    Qi, Honggang
    Luo, Kai
    Kang, Xiaonan
    Wang, Hang
    Huang, Yiran
    Zhang, Jin
    Xue, Wei
    EUROPEAN UROLOGY, 2023, 83 (02) : 163 - 172
  • [5] Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma
    Wang, Jiajun
    Zhang, Sihong
    Wang, Ying
    Zhu, Yanjun
    Xu, Xianglai
    Guo, Jianming
    CANCER MEDICINE, 2024, 13 (07):
  • [6] Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma
    Jiajun Wang
    Jinglai Lin
    Jiahao Wang
    Ying Wang
    Yanjun Zhu
    Xianglai Xu
    Jianming Guo
    Discover Oncology, 15
  • [7] The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition
    Wang, Jiajun
    Zhang, Sihong
    Wang, Ying
    Zhu, Yanjun
    Xu, Xianglai
    Guo, Jianming
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2023, 98 (04)
  • [8] Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma
    Wang, Jiajun
    Lin, Jinglai
    Wang, Jiahao
    Wang, Ying
    Zhu, Yanjun
    Xu, Xianglai
    Guo, Jianming
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [9] HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma
    Xu, Xianglai
    Zhang, Sihong
    Wang, Ying
    Zhu, Yanjun
    Wang, Jiajun
    Guo, Jianming
    CANCER MEDICINE, 2023, 12 (09): : 10512 - 10525
  • [10] Advanced Renal Cell Carcinoma: Tyrosine Kinase Inhibitors Versus Immune Checkpoint Inhibitors
    Rini, Brian I.
    ONCOLOGY-NEW YORK, 2022, 36 (08): : 511 - 515
12345